Clinical trial
A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX73086 as a Single Agent in Subjects With Advanced Solid Tumors and in Subjects With Locally Advanced or Refractory Tenosynovial Giant Cell Tumor (TGCT)
NCT02673736 is registered in ClinicalTrials.gov with Plexxikon as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX73086 as a Single Agent in Subjects With Advanced Solid Tumors and in Subjects With Locally Advanced or Refractory Tenosynovial Giant Cell Tumor (TGCT)
- Lead sponsor
- Plexxikon
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- February 29, 2016
- Completion date
- January 31, 2018
- Enrollment
- 11 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
solid tumors, synovitis, pigmented villonodular, tenosynovial giant cell tumor